The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 272-275

  Powles, T J ^a   Bourne, T ^c   Athanasiou, S ^b   Chang, J ^a   Grubock K ^b   Ashley, S ^a   Oakes, L ^a   Tidy, A ^a   Davey, J ^a   Viggers, J ^a   Humphries, S ^b   Collins, W ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHISTERONE; GESTAGEN; NORETHISTERONE; PLACEBO; PROGESTERONE; SODIUM CHLORIDE; TAMOXIFEN;

ARTICLE; BLEEDING; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYST; DOUBLE BLIND PROCEDURE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; FEMALE; HUMAN; HYSTEROSCOPY; ORAL DRUG ADMINISTRATION; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THICKNESS; TRANSVAGINAL ECHOGRAPHY;

EID: 7144255540     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.477     Document Type: Article

References (25)

1. Aleem F and Predanic M (1995) Endometrial changes in patients on tamoxifen. Lancet 346: 1292-1293
2. Bourne T, Lawton F, Leather A, Granberg S, Campbell S and Collins WP (1994) Use of intrasaline instillation and transvaginal ultrasonography to detect tamoxifen associated endometrial polyps. Obstet Gynaecol 4: 73-75
3. Carmichael P, Ugwumadu A, Neven P, Hewer A, Poon G and Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56: 1475-1479
4. Cohen I, Rosen D, Shapiro J, Cordoba M, Gilboa S, Altara M, Yigael D and Beyth Y (1993) Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100: 567-570
5. Cross S and Ismail S (1990) Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report. Br J Obstet Gynaecol 97: 190-192
6. De Muylder X, Neven P, Desomer M, Van Belle Y, Vanderick G and De Muylder E (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36: 127-130
7. Early Breast Cancer Trialists' Collaborative Group E (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1-15
8. Fornander T, Hellstrom A and Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850-1855
9. Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petilti D (1995) Hormone replacement therapy and endometrial cancer: a meta-analysis. Obstet Gynaecol 85: 304-313
10. Han X and Liehr JG (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363
11. Ismail S (1994) The pathology of tamoxifen-treated endometrium. J Clin Pathol 47: 827-833
12. Kedar R, Bourne T, Powles T, Collins W, Ashley S, Cosgrove D and Campbell S (1994) Effects of tamoxifen on the uterus and ovaries of women involved in a randomised breast cancer prevention trial. Lancet 343: 1318-1321
13. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P and Laatikainen T (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynaecol 81: 660-664
14. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16: 1651-1654
15. Neven P (1993) Tamoxifen and endometrial lesions. Lancet 342: 452
16. Neven P, De Muylder X, Van Belle Y, Vanderick G and De Muylder E (1990) Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynaecol Reprod Biol 35: 235-238
17. Phillips D, Potter G, Horton M, Hewer A, Crofton-Sleigh C, Jarman M and Venitt S (1994) Reduced genotoxicity of (D5-ethylotamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15: 1487-1492
18. Powles TJ (1992) The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340: 1145-1147
19. Powles T J and Hickish T (1995) Tamoxifen therapy and carcinogenic risk (editorial). J Natl Cancer Inst 87: 1343-1344
20. Powles T, Hardy J, Ashley S, Farrington G, Cosgrove D, Davey J, Dowsetl M, McKinna J, Nash A, Sinnett H, Tillyer C and Treleaven J (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer, Br J Cancer 60: 126-131
21. Powles T, Tillyer C, Jones A, Ashley S, Treleaven J, Davey J and McKinna J (1990) Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680-684
22. Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA and Davey JB (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82
23. Robinson S, Langan-Fahey L, Johnson D and Jordan V (1991) Metabolites. pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19: 36-43
24. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney L, Gimbrere C, Otter R, Schouten L, Dambuis R, Bontenbal M and Diepenhorst F (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452
25. White I, de Matteis F, Davies A, Smith L, Crofton-Sleigh C, Venitt S, Hewer A and Philips D (1992) Genotoxic potential of tamoxifen and analogues in female Fisher 344/n rats. DBA/2 and C57B2/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197-2203